Literature DB >> 1423598

Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

A S Plump1, J D Smith, T Hayek, K Aalto-Setälä, A Walsh, J G Verstuyft, E M Rubin, J L Breslow.   

Abstract

apoE-deficient mice have been created by homologous recombination in ES cells. On a low fat, low cholesterol chow diet these animals have plasma cholesterol levels of 494 mg/dl compared with 60 mg/dl in control animals, and when challenged with a high fat Western-type diet, these animals have plasma cholesterol levels of 1821 mg/dl compared with 132 mg/dl in controls. This marked hypercholesterolemia is primarily due to elevated levels of very low and intermediate density lipoproteins. At 10 weeks of age, apoE-deficient mice have already developed atherosclerotic lesions in the aorta and coronary and pulmonary arteries. apoE-deficient mice are a promising small animal model to help understand the role of apoE in vivo and the genetic and environmental determinants of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423598     DOI: 10.1016/0092-8674(92)90362-g

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  583 in total

1.  Angiotensin II, atherosclerosis, and aortic aneurysms.

Authors:  B C Berk; J Haendeler; J Sottile
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Love those mice!

Authors:  F C Luft
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

3.  Vascular hypercontractility and endothelial dysfunction before development of atherosclerosis in moderate dyslipidemia: role for nitric oxide and interleukin-6.

Authors:  Vanessa Cavieres; Karla Valdes; Brayan Moreno; Rodrigo Moore-Carrasco; Daniel R Gonzalez
Journal:  Am J Cardiovasc Dis       Date:  2014-10-11

4.  Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice.

Authors:  E D Reis; M Roque; H Dansky; J T Fallon; J J Badimon; C Cordon-Cardo; S J Shiff; E A Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

5.  A2b adenosine receptor regulates hyperlipidemia and atherosclerosis.

Authors:  Milka Koupenova; Hillary Johnston-Cox; Alexander Vezeridis; Haralambos Gavras; Dan Yang; Vassilis Zannis; Katya Ravid
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

6.  Increased atherosclerosis in hyperlipidemic mice deficient in alpha -tocopherol transfer protein and vitamin E.

Authors:  Y Terasawa; Z Ladha; S W Leonard; J D Morrow; D Newland; D Sanan; L Packer; M G Traber; R V Farese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

7.  Endothelial dysfunction in atherosclerotic mice: improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin.

Authors:  J Jiang; G Valen; S Tokuno; P Thorén; J Pernow
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

8.  Hepatic JAK2 protects against atherosclerosis through circulating IGF-1.

Authors:  Tharini Sivasubramaniyam; Stephanie A Schroer; Angela Li; Cynthia T Luk; Sally Yu Shi; Rickvinder Besla; David W Dodington; Adam H Metherel; Alex P Kitson; Jara J Brunt; Joshua Lopes; Kay-Uwe Wagner; Richard P Bazinet; Michelle P Bendeck; Clinton S Robbins; Minna Woo
Journal:  JCI Insight       Date:  2017-07-20

9.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.

Authors:  M Watanabe; J Osada; Y Aratani; K Kluckman; R Reddick; M R Malinow; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

10.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.